A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)

Trial Profile

A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)

Completed
Phase of Trial: Phase III

Latest Information Update: 29 May 2018

At a glance

  • Drugs Ramucirumab (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms REACH
  • Sponsors Eli Lilly; ImClone Systems
  • Most Recent Events

    • 29 May 2018 Results (n=565) of post hoc analyses of assessing AFP response and progression and their relationship with objective measures of response and survival were performed in patients from REACH, were published in the British Journal of Cancer.
    • 01 Aug 2017 Results assessing patient-focused outcome measures, including QoL and performance status (PS) from the REACH study, published in the European Journal of Cancer.
    • 11 Oct 2016 Results of a retrospective analysis on the survival and safety of patients by liver disease etiology presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top